Along with the development of direct IL-1β and TNF-α inhibition as a therapeutic strategy, attempts were made to use those baseline cytokine levels as predictive biomarkers of RA or markers of treatment responses, allowing for a better stratification of the patients and their clinical care. This evidence concerns the gene TNF and rheumatoid arthritis.